Ikarian Capital LLC Sells 185,171 Shares of Abeona Therapeutics Inc (NASDAQ:ABEO)

Ikarian Capital LLC trimmed its stake in Abeona Therapeutics Inc (NASDAQ:ABEO) by 24.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 583,593 shares of the biopharmaceutical company’s stock after selling 185,171 shares during the period. Ikarian Capital LLC’s holdings in Abeona Therapeutics were worth $3,688,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Simplify Asset Management Inc. bought a new position in shares of Abeona Therapeutics in the second quarter worth approximately $1,732,000. abrdn plc increased its position in shares of Abeona Therapeutics by 158.8% in the third quarter. abrdn plc now owns 326,995 shares of the biopharmaceutical company’s stock worth $2,067,000 after purchasing an additional 200,647 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of Abeona Therapeutics by 581.6% in the second quarter. Renaissance Technologies LLC now owns 503,293 shares of the biopharmaceutical company’s stock worth $2,134,000 after purchasing an additional 429,456 shares during the last quarter. Rosalind Advisors Inc. grew its position in Abeona Therapeutics by 4.7% during the third quarter. Rosalind Advisors Inc. now owns 1,832,000 shares of the biopharmaceutical company’s stock valued at $11,578,000 after acquiring an additional 82,000 shares during the last quarter. Finally, GSA Capital Partners LLP grew its position in Abeona Therapeutics by 54.3% during the third quarter. GSA Capital Partners LLP now owns 96,092 shares of the biopharmaceutical company’s stock valued at $607,000 after acquiring an additional 33,831 shares during the last quarter. 80.56% of the stock is currently owned by institutional investors.

Abeona Therapeutics Price Performance

NASDAQ ABEO traded down $0.11 on Tuesday, reaching $6.23. 8,372 shares of the company’s stock traded hands, compared to its average volume of 426,807. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12. Abeona Therapeutics Inc has a 12 month low of $3.05 and a 12 month high of $9.01. The stock has a market cap of $270.82 million, a PE ratio of -2.36 and a beta of 1.44. The stock has a 50-day simple moving average of $6.27 and a 200 day simple moving average of $5.37.

Analyst Upgrades and Downgrades

ABEO has been the topic of a number of recent research reports. StockNews.com upgraded shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, November 28th. Cantor Fitzgerald reiterated an “overweight” rating and set a $18.00 price target on shares of Abeona Therapeutics in a research report on Tuesday, October 29th. Finally, HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Abeona Therapeutics in a research report on Monday, November 25th.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.